{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:27:10Z","timestamp":1787646430707,"version":"build-2736575974"},"reference-count":52,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Advances in the molecular characterization of acute myeloid leukemia (AML) in recent decades have driven the development and clinical introduction of several targeted therapies, and menin inhibitors are the most recent additions to the therapeutic arsenal of AML treatments. The KMT2A and NPM1 loci have been the focus of intense investigation over the past two decades because of their well-established roles leukemogenesis, particularly in pre-clinical models of AML involving human xenografts. The ability of KMT2A and NPM1 aberrancies to drive and sustain leukemogenesis has provided a strong rationale for the development of therapeutic strategies to disrupt these molecular pathways. Menin inhibitors preferentially eliminate clones harboring KMT2A rearrangements or NPM1 mutations due to the dependence of these leukemia cells on the menin\u2013KMT2A complex and its downstream HOXA9\/MEIS signaling to sustain leukemic self-renewal and disease maintenance. In this review, we discuss the biological rationale for menin\u2013MLL disruption in patients with acute leukemia with KMT2A rearrangement or NPM1 mutation. We explore data from the landmark AUGMENT-101 and KOMET-001 trials, which have led to regulatory approval of revumenib and ziftomenib for select patients. We also explore cutting-edge studies using menin inhibitors in combination strategies, including data from KOMET-007. The evidence supporting combination approaches remains based on early-phase, single-arm trials with relatively short follow-up, and longer-term and comparative data are needed to define their clinical benefit. We highlight resistance mechanisms that have emerged from the use of contemporary menin inhibitors and efforts aimed at addressing this resistance, with a focus on emerging clinical data on enzomenib and bleximenib. Finally, we discuss prospects on the putative role of menin inhibitors in the measurable residual disease (MRD)-positive and maintenance settings in AML. Menin inhibitors have successfully transitioned from biological proof-of-concept to approved targeted therapy, and future advances will depend on rational front line combination strategies, MRD-guided treatment, post-transplant maintenance strategies, and therapeutic sequencing informed by mechanisms of resistance.<\/jats:p>","DOI":"10.3390\/cancers18172751","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:00:48Z","timestamp":1787644848000},"page":"2751","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Menin Inhibitors in Acute Myeloid Leukemia: Clinical Integration, Resistance, and the Path Beyond Monotherapy"],"prefix":"10.3390","volume":"18","author":[{"given":"Tina Y.","family":"Zhang","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, UMass Memorial Medical Center, UMass Chan Medical School, Worcester, MA 01655, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8208-1902","authenticated-orcid":false,"given":"Shyam A.","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, UMass Memorial Medical Center, UMass Chan Medical School, Worcester, MA 01655, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1548-918X","authenticated-orcid":false,"given":"Talha","family":"Badar","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, Mayo Clinic, Jacksonville, FL 32224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s12032-025-03192-4","article-title":"KMT2A-Mediated transcriptional regulation in stemness and cancer: Molecular mechanisms and therapeutic opportunities","volume":"43","author":"Sabuj","year":"2025","journal-title":"Med. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1182\/blood.2021012806","article-title":"The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML","volume":"139","author":"Heikamp","year":"2022","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood.2023021359","article-title":"Acute myeloid leukemias with UBTF tandem duplications are sensitive to menin inhibitors","volume":"143","author":"Barajas","year":"2024","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Joshi, U., and Shallis, R.M. (2026). Menin Inhibition in Acute Myeloid Leukemia: Pathobiology, Progress and Promise. Biomedicines, 14.","DOI":"10.3390\/biomedicines14010219"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/s41375-023-01877-1","article-title":"The KMT2A recombinome of acute leukemias in 2023","volume":"37","author":"Meyer","year":"2023","journal-title":"Leukemia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"26340","DOI":"10.1073\/pnas.2014732117","article-title":"Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23\/KMT2A","volume":"117","author":"Bill","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1182\/blood.2025028357","article-title":"Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: The AUGMENT-101 study","volume":"146","author":"Arellano","year":"2025","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1200\/JCO-25-01694","article-title":"Ziftomenib in Relapsed or Refractory NPM1-Mutated AML","volume":"43","author":"Wang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1200\/JCO-25-00914","article-title":"Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML","volume":"43","author":"Zeidner","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood-2025-47","article-title":"Phase II Study of the all-oral combination of revumenib (SNDX-5613) with decitabine\/cedazuridine (ASTX727) and venetoclax (SAVE) in newly diagnosed AML","volume":"146","author":"Jen","year":"2025","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Wang, E.S., Erba, H.P., Zeidan, A.M., Roboz, G.J., Altman, J.K., Advani, A.S., Lin, T.L., Strickland, S.A., Juckett, M.B., and Pratz, K.W. (2026). Ziftomenib with venetoclax and azacitidine in relapsed\/refractory NPM1-mutated acute myeloid leukemia. Blood.","DOI":"10.1182\/blood.2026034043"},{"key":"ref_14","unstructured":"Zeidan, A.M., Wang, E., Erba, H.P., Strickland, S., Issa, G., Balasubramanian, S., Roboz, G.J., McMahon, C., Rotta, M., and Madanat, Y.F. (2026, January 11\u201314). Ziftomenib combined with intensive induction (7+3) for newly diagnosed NPM1-m or KMT2A-r acute myeloid leukemia (AML): Long-term results from the KOMET-007 trial. Presented at 2026 European Hematology Association (EHA) Congress, Stockholm, Sweden. Abstract S130."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1182\/blood-2025-766","article-title":"Ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-m acute myeloid leukemia: Phase 1b results from KOMET-007","volume":"146","author":"Roboz","year":"2025","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1182\/blood-2024-204375","article-title":"Phase I\/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine\/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R\/R AML","volume":"144","author":"Issa","year":"2024","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1182\/bloodadvances.2025018178","article-title":"Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure","volume":"10","author":"Chin","year":"2026","journal-title":"Blood Adv."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood-2025-763","article-title":"Monotherapy update from Phase 1 portion in Phase1\/2 trial of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia","volume":"146","author":"Daver","year":"2025","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1182\/blood-2024-207106","article-title":"Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed\/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations","volume":"144","author":"Searle","year":"2024","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13045-025-01757-4","article-title":"A phase 1\/2 study of DS-1594 menin inhibitor in relapsed\/refractory acute leukemias","volume":"18","author":"Senapati","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1182\/blood-2025-765","article-title":"Preliminary data from the ongoing Phase 1 study of the menin-MLL inhibitor enzomenib (DSP-5336) in combination with venetoclax and azacitidine in patients with relapsed or refractory Acute Myeloid Leukemia","volume":"146","author":"Watts","year":"2025","journal-title":"Blood"},{"key":"ref_22","first-page":"S390","article-title":"Bleximenib in Combination with Intensive Chemotherapy: A phase 1b Study in Patients with Newly Diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 Alterations","volume":"32","author":"Schuh","year":"2026","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e70291","DOI":"10.1111\/cbdd.70291","article-title":"Targeting the Menin\u2013KMT2A Interface: Medicinal Chemistry Rules Governing Reversible, Covalent, and Degrader Inhibitors","volume":"107","author":"Eissa","year":"2026","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"117847","DOI":"10.1016\/j.ejmech.2025.117847","article-title":"Design, synthesis, and evaluation of Menin-targeting compounds for the treatment of acute Myelocytic leukemia (AML)","volume":"296","author":"Mo","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/S1470-2045(24)00386-3","article-title":"Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): A multicentre, open-label, multi-cohort, phase 1 trial","volume":"25","author":"Wang","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_26","unstructured":"Syndax Pharmaceuticals, Inc. (2026, August 18). REVUFORJ [Package Insert], Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=6eb3cdbc-0e74-477d-82d6-3bb172d3f63f."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/ajh.26142","article-title":"Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia","volume":"96","author":"Fathi","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood-2008-07-168617","article-title":"Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: Characteristics, outcome, and prognostic factors","volume":"113","author":"Montesinos","year":"2009","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1182\/blood.2024024008","article-title":"How I treat acute myeloid leukemia with differentiation therapy","volume":"145","author":"Issa","year":"2025","journal-title":"Blood"},{"key":"ref_30","unstructured":"Kura Oncology, Inc. (2016, August 18). KOMZIFTI Package Insert, Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=b650f696-3391-4274-8b55-a5f5e9d04769."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ajh.27584","article-title":"Treatment of Relapsed\/Refractory AML\u2014Novel Treatment Options Including Immunotherapy","volume":"100","author":"Moore","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6528","DOI":"10.1200\/JCO.2026.44.16_suppl.6528","article-title":"Pharmacokinetic (PK) assessment of revumenib in patients with relapsed\/refractory (R\/R) acute leukemias harboring a KMT2A rearrangement (KMT2A r) or NPM1 mutation (NPM1 m): Impact of food and concomitant medications","volume":"44","author":"Cobbina","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","article-title":"MEN1 mutations mediate clinical resistance to menin inhibition","volume":"615","author":"Perner","year":"2023","journal-title":"Nature"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.2025031201","article-title":"Discovery and preclinical activity of the menin-KMT2A inhibitor ziftomenib in acute leukemia models","volume":"148","author":"Miao","year":"2026","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6265","DOI":"10.1038\/s41467-026-72685-1","article-title":"CRISPR base editor screening identifies spectrum of MEN1 mutations impacting menin inhibitors in clinical trials","volume":"17","author":"Bourgeois","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1182\/blood.2023022480","article-title":"Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias","volume":"144","author":"Kwon","year":"2024","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/blood.2023023644","article-title":"Epigenetic regulation of noncanonical menin targets modulates menin inhibitor response in acute myeloid leukemia","volume":"144","author":"Zhou","year":"2024","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41408-021-00603-3","article-title":"Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)","volume":"12","author":"Fiskus","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1182\/blood.2025031486","article-title":"Overcoming menin inhibitor resistance in AML cells with combinations including BET proteins and a dual BRG1\/BRM inhibitor","volume":"147","author":"Fiskus","year":"2026","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/s41375-026-02959-6","article-title":"Overcoming MEN1-mediated resistance with menin inhibitor switching in KMT2A-rearranged acute myeloid leukemia","volume":"40","author":"Chin","year":"2026","journal-title":"Leukemia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1182\/blood-2023-173149","article-title":"Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R\/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study","volume":"142","author":"Lancet","year":"2023","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3324\/haematol.2012.079012","article-title":"HOXA\/PBX3 knockdown impairs growth and sensitizes cytogenetically normal acute myeloid leukemia cells to chemotherapy","volume":"98","author":"Dickson","year":"2013","journal-title":"Haematologica"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-023-00826-6","article-title":"Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1","volume":"13","author":"Fiskus","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ccell.2015.02.016","article-title":"Pharmacologic Inhibition of the Menin-MLL Interaction Blocks Progression of MLL Leukemia In Vivo","volume":"27","author":"Borkin","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_45","first-page":"S403","article-title":"Bleximenib or Placebo in Combination with Standard Induction and Consolidation Therapy Followed By Maintenance for the Treatment of Patients with Newly Diagnosed KMT2A-Rearranged or NPM1-Mutant Acute Myeloid Leukemia Eligible for Intensive Chemotherapy: A Double-Blind phase 3 Study (HOVON 181 AML\/AMLSG 37-25)","volume":"32","author":"Raaijmakers","year":"2026","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2026.44.16_suppl.TPS6602","article-title":"A phase 3 study of revumenib in combination with intensive chemotherapy in patients with newly diagnosed NPM1-mutated acute myeloid leukemia (REVEAL-ND NPM1)","volume":"44","author":"Stein","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1182\/blood.2020006575","article-title":"Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML models with activating FLT3 mutations","volume":"136","author":"Miao","year":"2020","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1182\/blood.2020005037","article-title":"Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition","volume":"136","author":"Dzama","year":"2020","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1182\/blood-2025-3427","article-title":"Preliminary Results of A phase 1 study of the safety and tolerability of the combination of revumenib (REV) with gilteritinib (GILT) in Relapsed\/Refractory (R\/R) Acute Myeloid Leukemia (AML)","volume":"146","author":"Borate","year":"2025","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1182\/blood.2025029712","article-title":"Menin inhibition enhances graft-versus-leukemia effects by T-cell activation and endogenous retrovirus induction in AML","volume":"147","author":"Fetsch","year":"2026","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2026.44.16_suppl.TPS6600","article-title":"A phase 3 study of revumenib plus venetoclax\/azacitidine in adults with newly diagnosed NPM1-mutated or KMT2A-rearranged acute myeloid leukemia ineligible for intensive chemotherapy (EVOLVE-2\/HO177\/AMLSG35-24\/ACT-HOV-AML-002)","volume":"44","author":"Huls","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.1182\/blood-2025-5211","article-title":"Trial in progress: A phase II study of ziftomenib monotherapy in unfit patients with newly diagnosed Acute Myeloid Leukemia with NPM1 mutation or KMT2A rearrangement","volume":"146","author":"Jain","year":"2025","journal-title":"Blood"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/17\/2751\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:07:21Z","timestamp":1787645241000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/17\/2751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":52,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["cancers18172751"],"URL":"https:\/\/doi.org\/10.3390\/cancers18172751","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]}}}